Nordic Bioscience’s unique biomarker PRO-C3 gets green light for further study in cancer from US FDA in formal Letter of Support

Paves way for further testing of the PRO-C3 biomarker assay, which identifies patients with hard to treat ‘fibrotic’ tumors, in further clinical trials US FDA recognizes need for a blood test for cancer aggressiveness which would be ‘potentially more accessible’ for patients than today’s tumor biopsy approach Potential to enable more targeted therapy and bring … Read more